Sue Jean Lin - Nov 24, 2025 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Director
Signature
/s/ Latha Vairavan, as Attorney-in-Fact for Sue-Jean Lin
Stock symbol
ARQT
Transactions as of
Nov 24, 2025
Transactions value $
-$567,945
Form type
4
Date filed
11/25/2025, 06:27 PM
Previous filing
Jun 16, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LIN SUE-JEAN Director C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE /s/ Latha Vairavan, as Attorney-in-Fact for Sue-Jean Lin 2025-11-25 0001867788

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Options Exercise $156K +18.1K +67.52% $8.63 44.8K Nov 24, 2025 Direct F1
transaction ARQT Common Stock Options Exercise $54.2K +7.22K +16.12% $7.51 52K Nov 24, 2025 Direct F2
transaction ARQT Common Stock Sale -$778K -25.3K -48.59% $30.78 26.7K Nov 24, 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (right to buy) Options Exercise $0 -18.1K -66.73% $0.00 9K Nov 24, 2025 Common Stock 18.1K $8.63 Direct F1
transaction ARQT Stock Option (right to buy) Options Exercise $0 -7.22K -59.08% $0.00 5K Nov 24, 2025 Common Stock 7.22K $7.51 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.
F2 The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
F3 The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $30.56 to $30.91, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.